RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity.
PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
干扰素基因刺激因子(STING)通路的激活可驱动自然杀伤(NK)细胞和T细胞协同 orchestrate 多维抗肿瘤免疫应答。尽管胞质DNA积累是STING激活的优越内源性策略,但DNA修复机制在很大程度上限制了其免疫原性潜力。在此,我们提出一种有前景的治疗策略,利用蛋白水解靶向嵌合体(PROTAC)介导的PARP1[聚(ADP-核糖)聚合酶1]和BRD4(含溴结构域蛋白4)降解来诱导合成致死,从而破坏驱动核到胞质DNA泄漏的DNA修复机制,超越STING激活阈值以点燃cGAS-STING介导的先天免疫。我们的策略在多种肿瘤模型中展现出优越的抗肿瘤疗效,引发强效的CD8+ T细胞和NK细胞介导的免疫,同时抑制肺转移进展。这种将合成致死与免疫原性应激反应相结合的策略,为通过cGAS-STING介导的先天免疫拓展广泛应用建立了一种此前未确定的范式。
Activation of the stimulator of interferon genes (STING) pathway drives natural killer (NK) cells and T cells to orchestrate multidimensional antitumor immune responses. While cytosolic DNA accumulation represents a superior endogenous strategy for STING activation, DNA repair machinery substantially constrains its immunogenic potential.
Here, we propose a promising therapeutic strategy that leverages proteolysis-targeting chimera (PROTAC)-mediated degradation of PARP1 [poly(ADP-ribose) polymerase 1] and BRD4 (bromodomain-containing protein 4) to induce synthetic lethality, thereby disrupting DNA repair machinery that drives nuclear-to-cytosolic DNA leakage, surpassing the STING activation threshold to ignite cGAS-STING-mediated innate immunity.
Our strategy demonstrates superior antitumor efficacy across multiple tumor models, eliciting robust CD8 + T cell- and NK cell-mediated immunity while suppressing pulmonary metastasis progression. This strategic integration of synthetic lethality with an immunogenic stress response establishes a previously unidentified paradigm for expanding broad applications by cGAS-STING-mediated innate immunity.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。